Latest Eisai Inc. Stories

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 31 - June 4, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) "These studies reinforce Eisai's strong and growing commitment to oncology, particularly to...

Will Lead Commercial Strategy for Eisai's Subsidiary in Mexico WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Ricardo Gonzalez Balboa to the position of General Manager, Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a direct subsidiary of Eisai Inc. In this position, Mr. Gonzalez Balboa will further develop and implement the company's commercial strategy in Mexico....

Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...

WOODCLIFF LAKE, N.J., May 7, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. This information is expected to be published in the Federal Register on May 8, with an effective date of June 7, 2013. Eisai will issue a public statement when BELVIQ is available in the U.S. BELVIQ was approved by the FDA on June 27, 2012 for chronic weight...

-- Arena to Receive $65 Million in Milestone Payments from Eisai -- SAN DIEGO, May 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ( )(pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal...

-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth -- WOODCLIFF LAKE, N.J., April 18, 2013 /PRNewswire/ -- Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7(th) Annual National Walk for Epilepsy, a family-oriented, non-competitive event to raise awareness and funds to continue fighting to stop seizures, find a cure and overcome the challenges created by epilepsy. The Walk, which unites thousands of families living with...

Newly Created Position to Strengthen Clinical Research WOODCLIFF LAKE, N.J., April 11, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels...

WOODCLIFF LAKE, N.J., March 26, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ACIPHEX(®) Sprinkle(TM) Delayed-Release Capsules 5mg and 10mg for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. "We are proud to offer a new treatment option for young children who suffer from GERD," said Lonnel Coats, president and CEO of Eisai Inc. "Eisai is committed to...

PARSIPPANY, N.J., March 5, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products,...

-- Conference Call and Webcast Scheduled for Today at 8:30 a.m. Eastern Time -- SAN DIEGO, March 4, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reviewed financial results for the fourth quarter and full year ended December 31, 2012. "2012 was a momentous year for Arena with the FDA approval of our first drug, BELVIQ," said Jack Lief, Arena's President and Chief Executive Officer. "It is a time of great pride, with BELVIQ...